Search Results - "WALLIS, Carole L"

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study by Hamers, Raph L, Dr, Schuurman, Rob, PhD, Sigaloff, Kim CE, MD, Wallis, Carole L, PhD, Kityo, Cissy, MD, Siwale, Margaret, MRCP, Mandaliya, Kishor, MBChB, Ive, Prudence, MD, Botes, Mariette E, MD, Wellington, Maureen, MBChB, Osibogun, Akin, Prof, Wit, Ferdinand W, MD, van Vugt, Michèle, MD, Stevens, Wendy S, Prof, de Wit, Tobias F Rinke, Prof

“…Summary Background The effect of pretreatment HIV-1 drug resistance on the response to first-line combination antiretroviral therapy (ART) in sub-Saharan…”
Get full text

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study by Hamers, Raph L, Dr, Wallis, Carole L, PhD, Kityo, Cissy, MD, Siwale, Margaret, MRCP, Mandaliya, Kishor, MBChB, Conradie, Francesca, MD, Botes, Mariette E, MD, Wellington, Maureen, MBChB, Osibogun, Akin, Prof, Sigaloff, Kim C E, MD, Nankya, Immaculate, PhD, Schuurman, Rob, PhD, Wit, Ferdinand W, MD, Stevens, Wendy S, Prof, van Vugt, Michèle, MD, de Wit, Tobias F Rinke, Prof

“…Summary Background There are few data on the epidemiology of primary HIV-1 drug resistance after the roll-out of antiretroviral treatment (ART) in sub-Saharan…”
Get full text

Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping by Aitken, Susan C, Wallis, Carole L, Stevens, Wendy, de Wit, Tobias Rinke, Schuurman, Rob

“…Dried blood spots (DBS) are an easy to collect sample-type that can stabilize biological material at ambient temperature for transport and storage, making them…”
Get full text

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings by Sluis-Cremer, Nicolas, Jordan, Michael R., Huber, Kelly, Wallis, Carole L., Bertagnolio, Silvia, Mellors, John W., Parkin, Neil T., Richard Harrigan, P.

“…•We looked for genetic differences at RPV resistance codons among HIV-1 subtypes.•E138A was found to occur more frequently in subtype C than B HIV-1…”
Get full text

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation by Paredes, Roger, Tzou, Philip L, van Zyl, Gert, Barrow, Geoff, Camacho, Ricardo, Carmona, Sergio, Grant, Philip M, Gupta, Ravindra K, Hamers, Raph L, Harrigan, P Richard, Jordan, Michael R, Kantor, Rami, Katzenstein, David A, Kuritzkes, Daniel R, Maldarelli, Frank, Otelea, Dan, Wallis, Carole L, Schapiro, Jonathan M, Shafer, Robert W

“…HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment…”
Get full text

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance by Salata, Robert A, Grinsztejn, Beatriz, Ritz, Justin, Collier, Ann C, Hogg, Evelyn, Gross, Robert, Godfrey, Catherine, Kumarasamy, Nagalingeswaran, Kanyama, Cecilia, Mellors, John W, Wallis, Carole L, Hughes, Michael D

“…Treatment management after repeated failure of antiretroviral therapy (ART) is difficult due to resistance and adherence challenges. For people who have failed…”
Get full text

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study by La Rosa, Alberto M, MD, Harrison, Linda J, MSc, Taiwo, Babafemi, MBBS, Wallis, Carole L, PhD, Zheng, Lu, PhD, Kim, Peter, MD, Kumarasamy, Nagalingeswaran, MD, Hosseinipour, Mina C, Prof, Jarocki, Bernadette, BS, Mellors, John W, Prof, Collier, Ann C, Prof

“…Summary Background For second-line antiretroviral therapy, WHO recommends a boosted protease inhibitor plus nucleoside or nucleotide reverse transcriptase…”
Get full text

Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100–200 cells/mm3 by Wykowski, James, Galagan, Sean R, Govere, Sabina, Wallis, Carole L, Moosa, Mahomed-Yunus, Celum, Connie, Drain, Paul K

“…Abstract Background Cryptococcal antigen (CrAg) screening with fluconazole prophylaxis has been shown to prevent cryptococcal meningitis and mortality for…”
Get full text

Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020 by Bekker, Linda-Gail, Brown, Benjamin, Joseph-Davey, Dvora, Gill, Kathrine, Moorhouse, Michelle, Delany-Moretlwe, Sinead, Myer, Landon, Orrell, Catherine, Rebe, Kevin, Venter, W D Francois, Wallis, Carole L

“…No abstract  available…”
Get full text

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy by Mahomed, Kairoonisha, Wallis, Carole L, Dunn, Liezl, Maharaj, Shavani, Maartens, Gary, Meintjes, Graeme

“…The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported…”
Get full text

A Pragmatic Approach to HIV-1 Drug Resistance Determination in Resource-Limited Settings by Use of a Novel Genotyping Assay Targeting the Reverse Transcriptase-Encoding Region Only by Aitken, Susan C, Bronze, Michelle, Wallis, Carole L, Stuyver, Lieven, Steegen, Kim, Balinda, Sheila, Kityo, Cissy, Stevens, Wendy, Rinke de Wit, Tobias F, Schuurman, Rob

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa by Sigaloff, Kim C E, Ramatsebe, Tina, Viana, Raquel, de Wit, Tobias F Rinke, Wallis, Carole L, Stevens, Wendy S

“…Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively…”
Get more information

Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial by Ive, Prudence, MacLeod, William, Mkumla, Nompumelelo, Orrell, Catherine, Jentsch, Ute, Wallis, Carole L, Stevens, Wendy, Wood, Robin, Sanne, Ian, Bhattacharya, Debika

“…Hepatitis B virus (HBV) infection is endemic in South Africa however, there is limited data on the degree of liver disease and geographic variation in HIV/HBV…”
Get full text

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial by Gross, Robert, Ritz, Justin, Hughes, Michael D, Salata, Robert, Mugyenyi, Peter, Hogg, Evelyn, Wieclaw, Linda, Godfrey, Catherine, Wallis, Carole L, Mellors, John W, Mudhune, Victor O, Badal-Faesen, Sharlaa, Grinsztejn, Beatriz, Collier, Ann C

“…Antiretroviral therapy (ART) non-adherence causes HIV treatment failure. Past behaviour might predict future behaviour; failing second-line ART could indicate…”
Get full text

Corrigendum: Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020 by Bekker, Linda-Gail, Brown, Benjamin, Joseph-Davey, Dvora, Gill, Kathrine, Moorhouse, Michelle, Delany-Moretlwe, Sinead, Myer, Landon, Orrell, Catherine, Rebe, Kevin, Francois Venter, W D, Wallis, Carole L

“…[This corrects the article DOI: 10.4102/sajhivmed.v21i1.1152.]…”
Get full text

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa by Wallis, Carole L., Mellors, John W., Venter, Willem D. F., Sanne, Ian, Stevens, Wendy

“…Limited data exist on HIV-1 drug resistance patterns in South Africa following second-line protease-inhibitor containing regimen failure. This study examined…”
Get full text

Development and Evaluation of an Affordable Real-Time Qualitative Assay for Determining HIV-1 Virological Failure in Plasma and Dried Blood Spots by Aitken, Susan C, Kliphuis, Aletta, Bronze, Michelle, Wallis, Carole L, Kityo, Cissy, Balinda, Sheila, Stevens, Wendy, Spieker, Nicole, de Oliveira, Tulio, Rinke de Wit, Tobias F, Schuurman, Rob

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone by Bronze, Michelle, Steegen, Kim, Wallis, Carole L, De Wolf, Hans, Papathanasopoulos, Maria A, Van Houtte, Margriet, Stevens, Wendy S, de Wit, Tobias Rinke, Stuyver, Lieven J

“…To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using…”
Get full text

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL by Taiwo, Babafemi O, Zheng, Lu, Stefanescu, Andrei, Nyaku, Amesika, Bezins, Baiba, Wallis, Carole L, Godfrey, Catherine, Sax, Paul E, Acosta, Edward, Haas, David, Smith, Kimberly Y, Sha, Beverly, Van Dam, Cornelius, Gulick, Roy M

“…Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. A5353 is a phase 2, single-arm, pilot…”
Get full text

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries by Wallis, Carole L., Godfrey, Catherine, Fitzgibbon, Joseph E., Mellors, John W.

“…The emergence and spread of human immunodeficiency virus (HIV) drug resistance from antiretroviral roll-out programs remain a threat to long-term control of…”
Get full text